LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger
LSBCF has more than doubled off its 52-week low of $0.028 on elevated volume (2.2× avg).
Summary
LakeShore Biopharma has scheduled an Extraordinary General Meeting for June 19, 2026, for shareholders to vote on the proposed going-private merger, which would delist the company and pay shareholders $0.09 per share.
Key Events · M&A and Partnerships · LSBCF
-
Shareholder Vote Scheduled
An Extraordinary General Meeting (EGM) is set for June 19, 2026, for shareholders to vote on the proposed going-private merger.
-
Merger Terms
The EGM will consider the Agreement and Plan of Merger, as amended on April 29, 2026, which proposes to take the company private at $0.09 per share.
-
Board Recommendation
The company's board of directors, based on a special committee's unanimous recommendation, advises shareholders to vote FOR the merger.
-
Delisting Imminent
If approved, the merger will result in LakeShore Biopharma becoming a privately held company, with its shares and warrants delisted from public markets.
Analysis · LSBCF · Life Sciences
This filing announces the date for the Extraordinary General Meeting where shareholders will vote on the proposed going-private merger. If approved, the company will delist, and shareholders will receive $0.09 per share, a price that was recently reduced. This is a critical procedural step towards the company's privatization, which will remove its shares from public trading.
At the time of this filing, LSBCF was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.